To include your compound in the COVID-19 Resource Center, submit it here.

Menlo's serlopitant meets in Phase II trial in chronic pruritus

In September, Menlo Therapeutics Inc. (Menlo Park, Calif.) reported data from the Phase II TCP-101 trial in 257 patients with chronic pruritus showing that

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE